SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
SERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug.
ADVERTISEMENT
About Nick Paul Taylor
This author has not written his bio yet.
But we are proud to say that Nick Paul Taylor contributed 23 entries already.
Entries by Nick Paul Taylor
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet
Harbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.
Isomorphic Labs raises $2.1B for AI-enabled drug discovery drive
Isomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform.
Infex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead asset
Infex Therapeutics has raised £4.3 million (€4.95 million) to advance an anti-infective pipeline led by a midphase drug candidate.
EktaH links novel obesity drug to fat loss, muscle retention in early-phase trial
EktaH has shared early clinical trial data on its first-in-class approach to treating obesity, encouraging the biotech to aim to advance the program into Phase 2 in the first half of next year.
Angelini inks $4.1B Catalyst takeover to fuel US expansion
Italy’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market.
Scarlet raises £3.2 million to advance lab-grown red blood cell therapies
Scarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have comparable half-lives.
Cytospire raises £61M to take gamma-delta T-cell engager into the clinic
Cytospire Therapeutics has raised a £61 million (€71 million) Series A round, positioning the British biotech to advance pan-gamma-delta T-cell engagers (TCEs) into cancer clinical trials.
MoonLake’s sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s Bimzelx
Most inflammatory arthritis patients on MoonLake Immunotherapeutics’ sonelokimab met the response criteria, furthering the Swiss biotech’s attempt to challenge UCB for a blockbuster market.
Forbion and Sanofi drive $75M investment in COPD biotech Altesa
Forbion has led a $75 million investment in Altesa BioSciences, positioning the biotech to run a phase IIb trial in chronic obstructive pulmonary disease (COPD) patients in the second quarter.